Abstract:Background: According to the ECDC’s latest report, Portugal has the highest incidence of HIV/AIDS and late diagnosis (lymphocyte TCD4+ count <350 cells/μL) in the European Union. Late diagnosis can significantly impact an individual’s health outcomes and the effectiveness of treatment interventions, interfering with overall health outcomes and quality of life. Objectives: Evaluate evolution of HIV diagnosis between 1998-2022 in a district Hospital comparing demographic, epidemiological, AIDS defining illnesses and mortality data. And evaluating the COVD-19 pandemic years regarding the late diagnosis impact, in this matter comparing 2020, 2021 and 2022 with 2017, 2018 and 2019. Methods: Retrospective study of HIV patients (pts) with TCD4+ <350 cells/μL at 1st visit between 1998-2018, divided into group A: TCD4+ <200 cells/ μL; group B: TCD4+ 200-350 cells/μL. Statistical analysis by Excel® from Microsoft 365®, by using the chi-squared test (χ2). Results: From a total of 1175 pts in IDS database, 649 met the criteria but due the lack of data, only 590 were admitted. From these, 63,73% (N=376) in group A and 36,27% (N=214) in B. Demographic and epidemiological characterization revealed (A vs B): male predominance of 79,52% vs 66.82% (p<0,0001); age at diagnosis<50 years 76,59% vs 84,11% (p<0,0001); transmission by heterosexual contact in 53,45% vs 50,93% (p<0,0001). At first health care encounter, 59,84% of group A had an AIDS defining illness-most commonly tuberculosis (33,33%). In a group analysis the percentage of pts in group A raised from 31,4% in 2018 to 32% in 2022. Analysis of mortality showed a death rate of 26,86% in group A versus 16,36% in group B (p<0,0001), with a mean duration from HIV diagnosis to death of 2208 days versus 2940 (p<0,0001). On average, time from first Infectious Diseases (ID) consultation to death was 1441 days in group A and 2308 in group B (p<0,0001). Analyzing before (2017-2019) and during COVID-19 (2020-2022), the prevalence of late presenters (<350 TCD4+/μl) went from 3.90% to 8.81% globally; an increase of 55.77% (23 to 52 pts), maintaining proportion of genders. During COVID-19 an increase in overall mortality was observed 26.86% vs 16.36% (group A vs B pre-pandemic) to 28.86% vs 18.92% (group A vs B pandemic) not due COVID infection. Conclusion: This study highlights the persistent challenge of late HIV diagnosis and its profound impact on patient outcomes. The demographic and epidemiological characterization underscores the need for targeted interventions to address disparities in testing and care access. The observed increase in late presenters and mortality rates during the COVID-19 pandemic underscores the importance of maintaining HIV care services amidst public health crises. Timely diagnosis, early intervention, and comprehensive care remain imperative to improve outcomes and advance towards the goal of ending AIDS as a public health threat by 2030.

Rapid CD4 cell count determination and Cryptococcus and Histoplasma antigen detection in people living with HIV: Implementation of a package of care strategy in a pilot study, Argentina

Evaluation of a rapid lateral flow immunoassay for the detection of cryptococcal antigen for the early diagnosis of cryptococcosis in HIV patients in Colombia

Implementation of a rapid diagnostic assay package for cryptococcosis, histoplasmosis and tuberculosis in people living with HIV in Paraguay

Implementation of Antigen-Based Diagnostic Assays for Detection of Histoplasmosis and Cryptococcosis among Patients with Advanced HIV in Trinidad and Tobago: A Cross-Sectional Study

Study on the application of CD4+ T lymphocyte rapid detection method in treating AIDS

Evaluation of an enzyme immunoassay technique on detecting urinary Histoplasma capsulatum antigen in the diagnosis of disseminated histoplasmosis in Argentina

Analysing Early Diagnosis Strategies for HIV Infection: A Retrospective Study of Missed Diagnostic Opportunities

Late Diagnosis in HIV: Experience of a Portuguese District Hospital between 1998-2022 (Too Late Study)

A prospective evaluation of the diagnostic accuracy of the point-of-care VISITECT CD4 Advanced Disease test in seven countries

Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain

Assessment of the performance of the plasma separation card for HIV-1 viral load monitoring in South Africa

Is it possible to control HIV infection in a middle-income country through a multidisciplinary approach?

Telemedicine in HIV health care during the COVID‐19 pandemic: An implementation research study in Buenos Aires, Argentina

Prevalence of Cryptococcal Antigenemia and Lateral Flow Assay Accuracy in Severely Immunosuppressed AIDS Patients

Advanced HIV Disease Burden in Selected Health Facilities in Mozambique, October–December 2023

Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: 'The ASAP study'

Feasibility and utility of active case finding of HIV-infected children and adolescents by provider-initiated testing and counselling: evidence from the Laquintinie hospital in Douala, Cameroon

Barriers and facilitators to implementing advanced HIV disease screening at a secondary referral hospital -Malawi: a convergent parallel study

Histoplasmosis, An Underdiagnosed Disease Affecting People Living With HIV/AIDS in Brazil: Results of a Multicenter Prospective Cohort Study Using Both Classical Mycology Tests and Histoplasma Urine Antigen Detection

Human immunodeficiency virus cascade-continuum of care stages and outcomes in a hospital in southern Brazil

Prevalence and associated factors of advanced HIV disease among ART-naïve and ART-experienced people with HIV at AHF-supported sites in Zambia